Fc receptor antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10479834-B2
Application number	US-201715830998-A
Country	US
Kind code	B2
Filing date	Dec 4, 2017
Priority date	Jun 2, 2011
Publication date	Nov 19, 2019
Grant date	Nov 19, 2019

Abstract

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

First claim

What is claimed is:

1. An isolated anti-neonatal Fc receptor (FcRn) antibody comprising a light chain variable region (V L ) and a heavy chain variable region (V H ), wherein the antibody binds to human FcRn;
wherein the V L comprises:
(i) a V L CDR1 comprising the amino acid sequence of SEQ ID NO:14;
(ii) a V L CDR2 comprising the amino acid sequence of SEQ ID NO:15; and
(iii) a V L CDR3 comprising the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13; and

wherein the V H comprises:
(i) a V H CDR1 comprising the amino acid sequence of SEQ ID NO:22;
(ii) a V H CDR2 comprising the amino acid sequence of SEQ ID NO:23; and
(iii) a V H CDR3 comprising the amino acid sequence of SEQ ID NO:24.

2. The isolated antibody of claim 1 , wherein the V L of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11.

3. The isolated antibody of claim 1 , wherein the V H of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 9.

4. The isolated antibody of claim 1 , wherein the isolated antibody is a human or humanized antibody or is non-immunogenic in a human.

5. The isolated antibody of claim 4 , wherein the isolated antibody comprises a human antibody framework region.

6. The isolated antibody of claim 1 , wherein the isolated antibody is a murine antibody.

7. The isolated antibody of claim 1 , wherein the isolated antibody is chimeric.

8. The isolated antibody of claim 1 , wherein the isolated antibody is a full-length antibody.

9. The isolated antibody of claim 1 , wherein the isolated antibody is selected from the group consisting of Fab, F(ab)′2, Fv, and scFv.

10. A pharmaceutical composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable carrier.

11. A method of detecting an FcRn in a sample or in a subject, the method comprising:
contacting the sample with the isolated antibody of claim 1 , and
detecting an interaction between the isolated antibody and the FcRn if present.

12. A method of modulating the half-life or level of a circulating IgG in a subject, the method comprising administering to the subject the isolated antibody of claim 1 in an amount effective to modulate the half-life or level of a circulating IgG in the subject.

13. The method of claim 12 , wherein the subject has an autoimmune disease or an inflammatory disorder.

14. The method of claim 12 , wherein the subject contains an unwanted IgG in the bloodstream.

15. The method of claim 14 , wherein the unwanted IgG is an anti-human leukocyte antigen (HLA) IgG antibody.

16. The method of claim 15 , wherein the subject has received an organ transplant.

Assignees

• Dyax Corp

Inventors

• Sexton Daniel J
• Tenhoor Christopher
• Viswanathan Malini

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title